Morgan Stanley
ETON icon

Morgan Stanley’s Eton Pharmaceutcials ETON Stock Holding History

Morgan Stanley’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8M Buy
767,972
+290,015
+61% +$8.5M ﹤0.01% 2785
2026
Q1 		$11.8M Sell
477,957
-15,957
-3% -$279K ﹤0.01% 3434
2025
Q4 		$8.35M Sell
493,914
-92,132
-16% -$1.62M ﹤0.01% 3756
2025
Q3 		$12.7M Buy
586,046
+76,478
+15% +$1.27M ﹤0.01% 3325
2025
Q2 		$7.26M Buy
509,568
+362,236
+246% +$5.73M ﹤0.01% 3744
2025
Q1 		$1.91M Buy
147,332
+134,139
+1,017% +$2.03M ﹤0.01% 4624
2024
Q4 		$176K Buy
13,193
+12,721
+2,695% +$129K ﹤0.01% 5840
2024
Q3 		$2.83K Buy
472
+280
+146% +$1.18K ﹤0.01% 7060
2024
Q2 		$632 Buy
192
+154
+405% +$539 ﹤0.01% 7203
2024
Q1 		$143 Hold
38
– – ﹤0.01% 7341
2023
Q4 		$166 Sell
38
-58
-60% -$233 ﹤0.01% 7315
2023
Q3 		$400 Sell
96
-748
-89% -$2.89K ﹤0.01% 7332
2023
Q2 		$2.95K Sell
844
-1,860
-69% -$6.84K ﹤0.01% 7111
2023
Q1 		$10.4K Sell
2,704
-5,437
-67% -$19.8K ﹤0.01% 6876
2022
Q4 		$23K Buy
8,141
+1,391
+21% +$3.74K ﹤0.01% 6630
2022
Q3 		$14K Sell
6,750
-1,685
-20% -$4.2K ﹤0.01% 6948
2022
Q2 		$23K Sell
8,435
-19,636
-70% -$65.9K ﹤0.01% 6923
2022
Q1 		$122K Sell
28,071
-2,001
-7% -$7.87K ﹤0.01% 6194
2021
Q4 		$129K Sell
30,072
-4,677
-13% -$22.4K ﹤0.01% 6291
2021
Q3 		$175K Buy
34,749
+33,159
+2,085% +$172K ﹤0.01% 6069
2021
Q2 		$10K Sell
1,590
-644
-29% -$4.77K ﹤0.01% 7226
2021
Q1 		$17K Sell
2,234
-16,069
-88% -$137K ﹤0.01% 6777
2020
Q4 		$149K Buy
18,303
+13,422
+275% +$104K ﹤0.01% 5736
2020
Q3 		$39K Sell
4,881
-5,439
-53% -$37.1K ﹤0.01% 5809
2020
Q2 		$56K Buy
10,320
+4,544
+79% +$22.6K ﹤0.01% 5638
2020
Q1 		$24K Buy
5,776
+670
+13% +$3.91K ﹤0.01% 5741
2019
Q4 		$36K Buy
5,106
+42
+0.8% +$259 ﹤0.01% 5941
2019
Q3 		$32K Buy
5,064
+2,800
+124% +$17.9K ﹤0.01% 5873
2019
Q2 		$18K Buy
+2,264
New +$17.6K ﹤0.01% 5967
2019
Q1 		– Sell
-400
Closed -$2K – 6620
2018
Q4 		$2K Buy
+400
New +$2.45K ﹤0.01% 6409

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Morgan Stanley's ETON Position: Q2 2026 in Review

Morgan Stanley increased its Eton Pharmaceutcials (ETON) stake by 61% in Q2 2026, buying an estimated $8.5M and bringing the position to 767,972 shares worth $27.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2785.

Morgan Stanley first reported a position in ETON in Q4 2018 and has held it in 30 quarters since. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Morgan Stanley held 767,972 shares of Eton Pharmaceutcials worth $27.8M as of Q2 2026.
  • Morgan Stanley bought 290,015 Eton Pharmaceutcials shares in Q2 2026, an estimated $8.5M.
  • Eton Pharmaceutcials made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2785 holding.
  • Morgan Stanley first reported a position in Eton Pharmaceutcials in Q4 2018 and has held it in 30 quarters since.
  • 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.